CELLECT BIOTECH/S (NASDAQ:APOP) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $0.88 and last traded at $0.91, with a volume of 684 shares traded. The stock had previously closed at $0.96.
Separately, Zacks Investment Research raised CELLECT BIOTECH/S from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a research note on Thursday, January 3rd.
The company has a market cap of $4.97 million, a price-to-earnings ratio of -1.10 and a beta of 2.42.
A hedge fund recently bought a new stake in CELLECT BIOTECH/S stock. Susquehanna International Group Ltd. bought a new position in shares of CELLECT BIOTECH/S (NASDAQ:APOP) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 11,964 shares of the company’s stock, valued at approximately $25,000. CELLECT BIOTECH/S comprises approximately 0.0% of Susquehanna International Group Ltd.’s investment portfolio, making the stock its 28th biggest position. Susquehanna International Group Ltd. owned approximately 0.22% of CELLECT BIOTECH/S as of its most recent SEC filing. Institutional investors and hedge funds own 2.57% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “CELLECT BIOTECH/S (APOP) Hits New 52-Week Low at $0.88” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/4299447/cellect-biotech-s-apop-hits-new-52-week-low-at-0-88.html.
About CELLECT BIOTECH/S (NASDAQ:APOP)
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
See Also: What are municipal bonds?
Receive News & Ratings for CELLECT BIOTECH/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELLECT BIOTECH/S and related companies with MarketBeat.com's FREE daily email newsletter.